Delivery of materials to anucleate cells
The current subject matter includes methods, systems, articles, and techniques to deliver material to anucleate cells, such as red blood cells. Using a rapid deformation based microfluidic system, loading of red blood cells with macromolecules of different sizes has been shown. Although delivery to some mammalian cells, such as cancer cell lines and fibroblasts had been previously demonstrated using this technique, those designs were incompatible with RBCs that have dramatically different physical properties. Through the use of smaller constriction sizes, high speeds and different buffers successful delivery to red blood cells can be achieved. By enabling robust delivery to red blood cells in a simple, scalable manner, the current subject matter can be implemented in a diversity of applications that deliver material to study red blood cell diseases and/or use red blood cells as a therapeutic platform. Related apparatus, systems, techniques, and articles are also described.
1. A method for delivering a payload into a mammalian anucleate cell comprising:
passing the anucleate cell suspended in a buffer through a microfluidic channel that includes a cell-deforming constriction, wherein the step of passing the anucleate cell through the constriction causes perturbations of the membrane of the anucleate cell large enough for the payload to pass through, wherein the constriction comprises a width, a length and a depth, wherein the width of the constriction is less than 4 micrometers;
incubating the anucleate cell in a solution comprising the payload for a predetermined time before or after the anucleate cell passes through the constriction; and
delivering the payload into the anucleate cell.
2. The method of claim 1 , wherein said cell is one or more of red blood cells, reticulocytes, and platelets.
3. The method of claim 2 , wherein said cell is a red blood cell.
4. The method of claim 1 , wherein said cell is a healthy cell.
5. The method of claim 4 , wherein said cell is a red blood cell.
6. The method of claim 1 , wherein said cell is an infected cell or a diseased cell.
7. The method of claim 6 , wherein said cell is a red blood cell.
8. The method of claim 1 , wherein the cell suspended in a buffer includes unmodified blood.
9. The method of claim 1 , wherein the width of the constriction is between 0.5 micrometer and 4 micrometers.
10. The method of claim 9 , wherein the width of the constriction is between 1 micrometer and 3 micrometers.
11. The method of claim 9 , wherein said cell is a red blood cell.
12. The method of claim 9 , wherein the width of the constriction is between 2 micrometers and 3 micrometers.
13. The method of claim 12 , wherein said cell is a red blood cell.
14. The method of claim 9 , wherein the width of the constriction is less than the largest diameter of the cell.
15. The method of any one of claim 9 , wherein the width of the constriction is about 20% to about 99% the largest diameter of the cell.
16. The method of claim 1 , wherein said buffer is a hypotonic buffer that causes said cell to swell.
17. The method of claim 1 , wherein said payload-containing solution comprises one or more of proteins, peptides, small molecules, nucleic acids, lipids, carbohydrates, macromolecules, vitamins, polymers, fluorescent dyes, fluorophores, carbon nanotubes, quantum dots, nanoparticles, dextran polymers, and steroids.
18. The method of claim 1 , wherein a cross-section of the microfluidic channel is selected from the group consisting of circular, elliptical, an elongated slit, square, hexagonal, and triangular.
19. The method of claim 1 , wherein incubating the cell in a payload-containing solution comprises incubating the cell for 0.0001 seconds to 60 minutes.
20. The method of claim 1 , wherein said length of the constriction is 30 micrometers or less.
21. The method of claim 1 , wherein said depth of the constriction is between 1 micrometer and 1 millimeter.
22. The method of claim 1 , wherein the microfluidic channel comprises a plurality of constrictions.
23. The method of claim 22 , wherein the plurality of constrictions is arranged in series and/or parallel.
24. The method of claim 23 , wherein the plurality of constrictions is arranged in parallel.
25. The method of claim 1 , wherein the length of the constriction is between 10 micrometers and 30 micrometers.
26. The method of claim 1 , wherein the length of the constriction is between 10 micrometers and 20 micrometers.
27. The method of claim 1 , wherein said payload includes one or more of atovaquone-proguanil, artemether/lumefantrine, quinine sulfate, mefloquine, hydroxychloroquine, quinidine, sulfadoxine/pyrimethamine, amodiaquine, sulfonamides, halofantrine, doxycycline, tetracycline, hydrea, acyclovir, ganciclovir, valacyclovir, or penciclovir.